# Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

> **NCT01662102** · PHASE3 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 1 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Zevalin
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01662102
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12-11
- **Primary completion:** 2013-03-05
- **Final completion:** 2013-03-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2021-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01662102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01662102, "Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01662102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*